Blue Lake Biotechnology and its parent company, University of Georgia spin off CyanVac, have announced the initiation of a Phase 1 trial of their CVXGA1 intranasal vaccine for the prevention of COVID-19. CVXGA1 is based on an attenuated strain of canine parainfluenza virus (PIV5). According to the two companies, the intranasal vaccine has demonstrated efficacy against infection and transmission of SARS-CoV-2 in animal models.
The Phase 1 trial is expected to enroll a total of 80 healthy adults, split into 40 participants between the ages of 18 and 55 years and 40 participants between the ages of 56 and 75. The younger group will be dosed first, receiving a single intranasal dose at one of two dose levels; the older group will follow with the same dosing.
CyanVac and Blue Lake Biotechnology President Biao He commented, “The enrollment of the first participant in our first-in-human Phase 1 clinical trial marks another important milestone in our rapid growth as a vaccine company. Our aim is to have a single-dose intranasal vaccine that can be used as a booster for existing vaccines, as well as a vaccine that can serve as a primary vaccine to countries that are struggling to acquire enough vaccine doses for their populations.”
The two companies are developing several other vaccines based on the PIV5 platform, including an intranasal vaccine against RSV that is expected to advance to Phase 1 development in the near future.
Read the Blue Lake Biotechnology and CyanVac press release.
